We also observed an improvement of his growth.After a 5-month treatment of cyclosporine A (CsA), proteinuria and hypoproteinemia have relieved apparently. We also observed an improvement of his growth. NT-proBNP and especially the changes in values are important markers in patients with congenital heart disease (CHD). NT-proBNP values determined from a urine sample correlate well with the plasma values of NT-proBNP. This study investigated the perioperative development of plasma and urinary values, examining their diagnostic and prognostic value. 83 children undergoing cardiac surgery for a myriad of CHDs were included. Urine and plasma samples were collected at different points in time. Urinary values were corrected for urine creatinine concentration and transformed into Lg10-values. The correlation between urine and plasma is weaker postoperatively (r=0.70-0.80) in comparison to preoperatively (r=0.87). Neonates had higher urinary values than older children. A ROC-analysis for the differentiation between complex and simple CHD showed an area under the curve of 0.854 for zlog-NT-proBNP plasma values and 0.826 for creatinine corrected urine values. A decline of NT-proBNP plasma values from the day before surgery to the time after intubation correlated with the duration of postoperative non-invasive ventilation (r=0.9, sig.<0.001). Urinary NT-proBNP shows potential in discriminating between complex and simple CHD. This study is the first to show a prognostic role of NT-proBNP in establishing spontaneous respiration postoperatively in children with CHD.Urinary NT-proBNP shows potential in discriminating between complex and simple CHD. This study is the first to show a prognostic role of NT-proBNP in establishing spontaneous respiration postoperatively in children with CHD. Decreased serum netrin-1 concentrations have been found after acute brain injury. We investigated the role of serum netrin in prognosis of traumatic brain injury (TBI). In this prospective and observational study, enzyme-linked immunosorbent assay was used to detect serum netrin-1 concentrations in 50 mild TBI patients (Glasgow coma scale (GCS) score, 13-15), 83 moderate TBI patients (GCS score, 9-12), 69 severe TBI patients (GCS score, 3-8) and 50 healthy controls. Glasgow outcome scale score of 1-3 at 6months after trauma was defined as poor outcome. Serum netrin-1 concentrations were significantly lower in moderate or severe TBI patients than in controls and in severe TBI patients than in moderate TBI patients, while not in mild TBI patients than in controls. GCS score and Rotterdam computed tomography classification were closely correlated with serum netrin-1 concentrations among TBI patients. AR-13324 purchase Forty-two (20.8%) patients had poor outcome. Receiver operating characteristic curve analysis revealed that serum netrin-1 concentrations could distinguish patients with poor outcome from the other remainders significantly. In addition, serum netrin-1 concentrations were independently associated with poor outcome. Serum netrin-1 might serve as a potential biomarker for prognosis of TBI.Serum netrin-1 might serve as a potential biomarker for prognosis of TBI. We compared two serological assays from Roche Diagnostics in individuals with and without COVID-19 vaccination, namely the Elecsys Anti-SARS-CoV-2 assay (detecting antibodies against the nucleocapsid protein of SARS-CoV-2) and the Elecsys Anti-SARS-CoV-2 S assay (detecting antibodies against the spike protein of SARS-CoV-2). With both assays, we analyzed 3033 serum samples collected from 2496 patients without COVID-19 vaccination. In addition, we studied 34 healthcare-workers who received two injections of the BNT162b2 COVID-19 vaccine from BioNTech/Pfizer three weeks apart and who had repeatedly determined their antibody response by both assays. In our cohort of patients without COVID-19 vaccination, 62.9% of all determinations were negative with both Roche assays and 31.5% were positive with both assays. In 5.6% of our cohort, however, there were discordant results with both assays (partly because initially discordant results of the two assays became concordantly positive over time). In the healthcare-workers with the COVID-19 vaccination, the results of the Roche anti-nucleocapsid assay remained negative throughout the observation period of 5weeks after vaccination. The initially negative antibodies against the spike protein became positive with the Roche assay in all samples two weeks after the initial injection, and the serum concentrations of anti-spike antibodies increased constantly until 4-5weeks after the initial injection. Here, we provide information on serological testing with the two Roche assays, which may be important for the application of the two assays in clinical routine. There are differences in the pattern of antibodies in individuals with and without COVID-19 vaccination.Here, we provide information on serological testing with the two Roche assays, which may be important for the application of the two assays in clinical routine. There are differences in the pattern of antibodies in individuals with and without COVID-19 vaccination.Atherosclerosis, a disease process characterized by lipid accumulation and inflammation, is the main cause of coronary heart disease (CHD) and myocardial infarction (MI). Efferocytosis involves the clearance of apoptotic cells by phagocytes. Successful engulfment triggers the release of anti-inflammatory cytokines to suppress atherosclerosis. ABCA1 is a key mediator of cholesterol efflux to apoA-I for the generation of HDL-C in reverse cholesterol transport (RCT). Intriguingly, ABCA1 promotes not only cholesterol efflux but also efferocytosis. ABCA1 promotes efferocytosis by regulating the release of "find-me" ligands, including LPC, and the exposure, release, and expression of "eat-me" ligands, including PtdSer, ANXA1, ANXA5, MEGF10, and GULP1. ABCA1 has a pathway similar to TG2, which is an "eat-me" ligand. ABCA1 has the highest known homology to ABCA7, which controls efferocytosis as the engulfment and processing ligand. In addition, ABCA1 can form several regulatory feedback axes with ANXA1, MEGF10, GULP1, TNFα, and IL-6.